FDA investigate two deaths after treatment with Schizophrenia drug Zyprexa Relprevv (Eli Lilly)

Following the deaths of two patients with Schizophrenia who had received intramuscular injections with Eli Lilly's Zyprexa Relprevv (olanzapine pamoate), the FDA has started an investigation. The patients died several days after treatment, in a time window which is outside the three-hour post-injection monitoring period required under the product's risk evaluation and mitigation strategy. The drug carries a risk of post-injection delirium sedation syndrome.

Eli Lilly spokesman Morry Smulevitz commented: "Based on the information available to us, we are unable to conclude whether the two deaths were related to administration of Zyprexa Relprevv." Zyprexa Relprevv was approved for Schizophrenia by the FDA in 2009.